TickerFacts.

NewAmsterdam Pharma Co N.V. (NAMS): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

-$225.46M
Year ended 2025-12-31
-$244.16M
Trailing 12 months to 2026-06-30
2021-12-31: -$34.97M2022-12-31: -$3.55M2023-12-31: -$182.92M2024-12-31: -$176.18M2025-12-31: -$225.46M-$225.46M
2021-12-31 EBITDA (USD) 2025-12-31
Period endedEBITDAChange YoYSource filing
2025-12-31-$225.46Mn/m2026-02-18, From 2025-01-01
2024-12-31-$176.18Mn/m2026-02-18, From 2024-01-01
2023-12-31-$182.92Mn/m2026-02-18, From 2023-01-01
2022-12-31-$3.55Mn/m2025-02-26, From 2022-01-01
2021-12-31-$34.97Mn/a2024-02-28, From 2021-01-01

EBITDA at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEBITDAChange YoY
NewAmsterdam Pharma Co N.V. (NAMS)2025-12-31-$225.46Mn/m
Alumis Inc. (ALMS)2025-12-31-$450.31Mn/m
CASI Pharmaceuticals, Inc. (CASIF)2025-12-31-$43.81Mn/m
Scynexis Inc (SCYX)2024-12-31-$37.12Mn/m
Sol-Gel Technologies Ltd. (SLGL)2025-12-31-$7.43Mn/m
Celularity Inc (CELU)2025-12-31-$54.01Mn/m
Cue Biopharma, Inc. (CUE)2025-12-31-$25.59Mn/m
Foghorn Therapeutics Inc. (FHTX)2025-12-31-$83.06Mn/m
uniQure N.V. (QURE)2025-12-31-$170.59Mn/m

Compare NAMS, ALMS, CASIF, SCYX side by side · Screen every company in Pharmaceutical Preparations ↗